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Multiple myeloma (MM) accounts for around 15% of new cases
and 20% of deaths amongst patients diagnosed with haemato-
logical malignancy. To date, few risk factors have been robustly
confirmed for MM, these include increasing age, male sex, black
race and a family history of MM.1
High body mass index (BMI) has been reported to be associated
with an increased risk of MM in several observational studies,
though questions remain regarding the aetiological relevance,
including the distribution of body fat.2 In addition to being a
potential risk factor for MM, some, but not all, studies have
suggested an association between BMI and prognosis.1,3 A recent
study has suggested the relationship between BMI and MM may
be through reduced levels of plasma adiponectin, the inflamma-
tory mediator secreted by adipocytes. The association was,
however, confined to obese individuals providing an argument
against a direct causal link.4 Findings such as these, alongside the
conflicting results of previous studies into adiposity traits, high-
light the limitations of observational studies. Importantly, such
studies do not establish a causal relationship, as they cannot fully
eliminate the influence of confounding factors. Moreover, in the
context of prognostication, many studies have not explicitly
addressed the issue of reverse causation.5
Mendelian randomisation (MR) provides an attractive alterna-
tive to the traditional epidemiological study for examining
relationships between exposure and disease. MR makes use of
allelic variants, which are randomly assigned during meiosis and
are robustly associated with traits of interest, as instrumental
variables (IVs) to infer whether associations between exposure and
disease are causal. The use of these genetically defined IVs as
proxies of modifiable exposure, avoids confounding by environ-
mental factors, can be reflective of life-long exposure and
circumvents reverse causality.
Genome-wide association studies (GWAS) have identified single-
nucleotide polymorphisms (SNPs) at multiple independent loci
significantly associated with BMI, childhood obesity (CHO) and
plasma levels of adiponectin.6–8 Here we have sought to establish a
causal association between adiposity traits and MM by performing a
MR analysis using SNPs associated with body mass index (BMI), hip
circumference adjusted for BMI (HipadjBMI), waist circumference
adjusted for BMI (WCadjBMI), waist-to-hip ratio adjusted for BMI
(WHRadjBMI), CHO and plasma adiponectin levels as IVs.
We constructed genetic risk scores (GRS), to investigate the
relationship of adiposity and plasma levels of adiponectin with MM
risk, using the data from five reported MM GWASs, comprising 6 839
cases and 22 221 controls.9 We performed two-stage MR analysis to
assess the association between each adiposity trait and MM using
summary statistics from the MM GWAS, and the published effect size
of the adiposity trait. As per Burgess et al.,10 a fixed-effects model
was used to calculate combined ratio estimates, β, for the effect of
each trait on MM risk. Results are summarised in Table 1.
Following calculation of combined ratio estimates, β, in three of
the five cohorts, a positive association was shown between one s.
d. in BMI (kg /m2) and MM risk, with the UK-GWAS series being
nominally significant (Figure 1a). Meta-analysis of the data from all
five cohorts did not, however, provide evidence for a causal
association (odds ratio (OR) = 1.17, 95% confidence intervals (CIs):
0.92–1.49, P= 0.19). Similarly, we found no association between
the other anthropometric traits, which report on central obesity
and MM risk, specifically—HipadjBMI, WCadjBMI, WHRadjBMI,
which had respective ORs of 0.77 (95% CI: 0.42–1.41), 0.62 (95% CI:
0.37–1.02) and 0.82 (95% CI: 0.57–1.19) (Figures 1b–d). We also
found no support for a relationship between CHO and MM risk
(OR= 0.98, 95% CI: 0.87–1.10; Figure 1e). We then evaluated the
impact of plasma levels of adiponectin on the risk of developing
MM, again observing no association (OR= 1.04, 95% CI: 0.64–1.72;
Figure 1f).
Linkage of the survival data to genotypes on three of the series
allowed the relationship between the aforementioned adiposity-
related traits and patient outcome to be examined through MR. In
meta- analyses of these data, no association between any of the
traits and either overall survival (OS) or progression-free survival
(PFS) was shown.
The results from our study contrast with some observational
epidemiological studies, which have shown a positive association
between adiposity and MM risk and mortality.1,11 A recent meta-
analysis of studies found a modest, but significant association
between BMI and risk in prospective cohorts.11 Reported relative
risks for MM associated with obesity from these studies had OR 95%
CIs of 1.08–1.35. Over this range of effect, we had 16–97% study
power to demonstrate an association. Hence, we cannot exclude
the possibility that the null results we observed were simply a
consequence of limited study power if the true effect is marginal.
Obesity is a well-established risk factor for a number of other
solid cancers.12 By inference, it is likely a priori that obesity will also
increase MM risk. An elevated level of insulin-like growth factor 1,
associated with chronic hyperinsulinemia, stimulates cell prolif-
eration and inhibits apoptosis, therefore providing a biological
basis for obesity having a generic effect on cancer risk.13 In the
case of MM, the insulin receptor is overexpressed in MM cells and
is increased throughout normal plasma cell differentiation.14
These observations would therefore imply a causative effect of
Table 1. Results of associations of multiple myeloma (MM) risk with
adiposity traits using Mendelian randomisation
Trait Odds ratio 95% CI P-value
BMI 1.17 0.92;1.49 0.19
CHO 0.98 0.87;1.10 0.71
WHRadjBMI 0.82 0.57;1.19 0.29
WCadjBMI 0.62 0.37;1.02 0.06
HipadjBMI 0.77 0.42;1.41 0.39
Adiponectina 1.04 0.64;1.72 0.86
Abbreviations: BMI, body mass index; CHO, childhood obesity; HipadjBMI,
hip circumference adjusted for BMI; WCadjBMI, waist circumference
adjusted for BMI; WHRadjBMI, waist-to-hip ratio adjusted for BMI. Odds
ratio, 95% confidence intervals (CIs) and and P-values from meta-analysis of
all cohorts, which demonstrates no significant causative effect of traits on
MM risk. aMeta-analysis for adiponectin was conducted with 3 cohorts as
no SNPs were present in UK and USA data sets.
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obesity and ensuing hyperinsulinemia on plasma and myeloma
cell growth; a corollary of this may be increased risk of MM and
adverse patient outcome.
Our MR analysis does not suffer from the influence of recall bias
and confounding that can affect observational studies.5 Never-
theless, a central assumption in MR is that the variants used as IVs
are associated with the exposure being investigated. To ensure
this was the case, we only used SNPs associated with adiposity-
related traits at genome-wide significance from GWAS. Further-
more, we only used the data from individuals of European descent
to limit bias from population stratification. An additional assump-
tion is that the variants are associated with MM only through the
exposure and are not confounded by pleiotropy. We assessed the
impact of possible pleiotropism on MR estimates using both
inverse variance weighted (IVW) and MR-Egger regression tests as
per Bowden et al.15 Neither test provided evidence for pleiotropy,
with respective P-values of 0.2 and 0.71 for BMI, 0.77 and 0.65 for
CHO, 0.56 and 0.52 for HipadjBMI, 0.13 and 0.66 for WCadjBMI, 0.4
and 0.79 for WHRadjBMI, and 0.87 and 0.2 for adiponectin plasma
levels. While we found no evidence that the SNPs violated this IV
assumption, this does not exclude confounding by as yet
unidentified confounders.
In conclusion, high BMI is a plausible risk factor for MM;
however, observational studies so far have provided varied and
conflicting results, likely attributed to confounding and reverse
causation. Our MR study, which uses IVs to avoid such
confounding factors, provides no evidence of BMI or other tested
adiposity traits, influencing MM risk or survival. To robustly
establish a causal relationship through MR-based analyses, and
thus avoid confounding, far larger datasets will be required than
the one we have analysed. Such studies should be possible in the
future with ongoing GWASs of MM currently being undertaken.
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